top of page
The Professional Network for Healthcare Experts
China NMPA approves Foresee's Camcevi 42 mg six-month injection for advanced prostate cancer
China's NMPA has approved Foresee Pharmaceuticals' Camcevi 42 mg, a ready-to-use six-month leuprolide injection for adults with advanced prostate cancer.
nuaxia
23 hours ago2 min read
China healthcare salaries rise in 2025 as official data reveals private and non-private pay gap
Average annual salaries across China's health and social work sector increased in 2025, with employees in urban non-private organisations earning almost twice the average recorded in private organisations, according to new official data.
nuaxia
Oct 23 min read
Insilico Medicine and China Medical System Expand AI Drug Discovery Partnership with $177m CNS Deal
The latest agreement strengthens the companies’ collaboration as they target a major central nervous system indication using AI-powered drug discovery.
nuaxia
Jul 143 min read
AstraZeneca Expands China Partnerships with Up to $2.1bn Respiratory Drug Deal
The agreement with Sino Biopharmaceutical gives AstraZeneca ex-China rights to TQC3721, an experimental dual PDE3/4 inhibitor being developed for chronic respiratory diseases.
nuaxia
Jul 93 min read
Big Pharma Isn’t Just Buying From China Anymore — It’s Building With It
Bristol Myers Squibb’s expanding partnership strategy signals how China is evolving from a biotech sourcing market into a core pillar of global pharmaceutical R&D
nuaxia
May 152 min read
bottom of page